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newly-diagnosed patients by 84% respondents. A similar per-
centage of the doctors (85%) preferred olmesartan over the other
ARBs. Ninety percent of the doctors responded that olmesartan
provided both “rapid control of BP” and “maximum reduction of
BP” in comparisonwith the other ARBs. In patients with T2DM and
nephropathy ~70% doctors prefer olmesartan over the other sar-
tans. Additionally, the triple drug combinations of olmesartan
were preferred over the triple drug combinations of telmisartan.
Conclusions: This survey has demonstrated that Indian doctors
use ARBs as a first-line antihypertensive, which is supported by
the recent guidelines. Amongst the ARBs, olmesartan is preferred
for the treatment of hypertension and is associated with the
properties of prompt reduction of BP and strong reduction of BP.
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Background: Microalbuminuria is a powerful predictor of cardio-
vascular events and is considered as target organ damage in pa-
tients with essential hypertension. The purpose of the present
study was to explore the effect of current smoking on micro-
albumin excretion in patients with essential hypertension.
Methods: The study comprised 200 consecutive patients with
essential hypertension who visited our outpatient clinic from
-2013 TO 2014. All patients underwent full clinical, laboratory and
screening evaluation. Patients under treatment followed a wash-
out period at least for 15 days. All subjects underwent a 24hour
urine sample collection and thus microalbumin, albumin-crea-
tinin ratio (ACR) and 24h creatinin clearance were measured.
Smoking habits were assessed by means of a standard
questionnaire.
Results: Patients were divided in two groups according to their
current smoking habits: group I (n¼127 non-smokers) and group II
(n¼73 smokers). Smokers were younger (P¼0.001), had higher
diastolic blood pressure (DBP) (P<0.001), greater microalbumin
levels (P<0.001), higher ACR (P<0.001) and higher body mass index
(BMI) (P¼0.03) compared to non-smokers. The two groups had no
differences in systolic blood pressure (SBP), renal hemodynamics,
glucose levels and 24h creatinin clearance (P¼NS). After multi-
variate analysis was performed smoking remained significant
determinant of higher ACR and microalbumin levels (P<0.0001)
independently of DBP, BMI and age.
Conclusions: Smoking is associated with greater microalbumin
excretion in patients with essential hypertension. Thus smoking
may pose a burden to renal function in these subjects.
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Background: Takayasu arteritis (TA) with stenosis of renal arteries
frequently presents with hypertension in young adults.
Angioplasty of these lesions is expected to control hypertension
and renal damage. We present the long term results of renal an-
gioplasty done over 5 years in our hospital.
Methods: All cases of Takayasu arteritis that underwent renal
angioplasty from 2006 to 2011 were followed up clinically and by a
renal Doppler in all cases. A cine renal- angiogram was advised at
6 months and 18 month visit. We performed renal angioplasty in
56 lesions (48 patients; 34 females; age range 22 to 46 years; mean
28.5±4.65 years). Unilateral lesions were seen in 40 patients and
rest had one lesion in each renal artery. Of them 34 cases with at
least 24 months follow-up data were included for analysis.
Results: Technical success rate was 89.3 %( 50/56) lesions with no
MACE at 30 days. Of the 6 failure cases one with bilateral lesions
was sent for emergency surgery due to renal artery rupture
following PTRA. The 3 of the rest 5 underwent elective surgical
revascularization. On a mean follow up of 26.5±8.5months, 12 of
34 cases (14 of 37 lesions (37.8%) developed restenosis and 10 of
them were successfully redilated. There was death of one patient
with bilateral lesions due to CRF.
Cure of hypertension (BP <140/90 mmHg without need for
medication) and improvement (BP<140/90 mmHg with same or
reduced number ofmedications) was achieved in 12/34(35.3%) and
10/34(29.4%) respectively. Of the 15 cases with raised serum
Creatinine7/15 (49.7%) had shown a fall in their values in follow-
up (mean 1.71± 1.05mg to 1.1±0.76 mg; p-<0.005)
Conclusion: While acute results were satisfactory, the restenosis
was seen in about one-third of the cases after an initial successful
procedure most of which could be redilated. Control of hyperten-
sion and renal dysfunction was achieved in a significant number.
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Background: Hypertension is one of the most important contrib-
utors to heart disease and stroke which together make up the
world’s number one cause of premature death and dis-
ability.Since the time statins have been introduced,several pleio-
tropic effects of statins that have been described.In the past few
years ,another effect of statins has been proposed that statinsmay
also lower blood pressure and thus act through a reduction in the
blood pressure related risk. Because endothelial dysfunction plays
a significant role in the pathogenesis of arterial hypertension, it is
reasonable to search for new strategies aimed at improving
endothelial function.
Aim: To study the effect of rosuvastatin therapy in normocho-
lesterolemic patients when added to antihypertensive agent on: a)
Blood pressure in stage 1 hypertensive individuals.b)Endothelial
functionand oxidative stress levels in stage 1 hypertensive
individuals.
Methods: It was a randomized double blind study conducted over
a period of 1year. Total 100 cases of stage 1 hypertensive normo-
cholesterolemic subjects who were not on any lipid lowering drug
were recruited and divided into two groups: Group A (antihyper-
tensive agent+rosuvastatin) and Group B (antihypertensive
agent+placebo). The patients were followed up every two weeks
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 1es 1 4 3 S91
for their BP recordings. All routine and special investigations i.e.
flow mediated dilation (FMD), Ferric Reducing ability of plasma
(FRAP) & Malondialdehyde (MDA) were done in beginning as well
as at the end of 8 weeks.
Results: The reduction in mean SBP (-2.56mmHg), pulse pressure
(-1.88), total cholesterol (-18.10mg/dl) and triglyceride (-18.88mg/
dl) were significant (p<0.001) in rosuvastatin group but not in
placebo (p¼0.0722). Also, significant improvement in mean FMD
(+4.34%) and mean antioxidant (FRAP) was observed in rosuvas-
tatin group and however no such changes were seen in placebo
group (p¼0.73). There were no significant changes in diastolic
blood pressure and MDA levels in both rosuvastatin as well as
placebo group.
Conclusions: The addition of rosuvastatin in normocholester-
olemic subjects led to significant fall in mean systolic blood
pressure and mean pulse pressure with improvement of endo-
thelial function and antioxidant levels. Rosuvastatin can suppress
progression of atherosclerosis, decrease serum CRP production
and reduce cardiovascular events.This study reinforces relatively
poorly understood and under-reported hypotensive potential of
statin, one of many pleiotropic effect associated with the class of
statin.The reduction of systolic blood pressure and pulse pressure
have been strongly linked to reduced incidence of stroke in hy-
pertension and any intervention leading to reduction in these
parameters however small will go a long way in arresting the
crippling consequences.
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Background: Accelerated/Malignant hypertension (A/MH) is a
hypertensive emergency, clinically defined by the European so-
ciety of Hypertension/European society of cardiology (ESH/ESC) as
the presence of very high BP associated with target organ damage
(TOD) [retina, kidney, heart or brain]. The 5 years survival rate
reported after the diagnosis of A/MH has improved significantly
which could be due to earlier diagnosis, lower BP targets and
availability of new classes of antihypertensive agents.
Objective: To estimate the incidence of A/MH and evaluate its
prognosis and management.
Methods: A retrospective cohort analysis was carried out at our
2500 bedded tertiary care teaching hospital on patients admitted
with essential HTN (during 2008 - 2012) with ICD e 10 (I.10) coding
with no comorbidities with age40 were considered for the study.
Results: Of the 305 in-patients diagnosed with essential HTN, 17
(5.8%) were found to have Grade III HTN (ESH/ESC 2013) which
were documented as A/MH. Male predominance was found to be
higher with 53% with a mean age for 58 years (±10 SD) and mean
BMI of 23.8 (±4.7 SD). TOD identified in 17 patients were: 2 patients
(12%) ophthalmic, 9 (53%) left ventricular failure and none re-
ported in 6 (35%). All patients except one were treated with
amlodipine (88%) either as monotherapy or with other classes
including ARBs, ACEi, diuretics, beta blockers or clonidine. Read-
missions were reported in 5 (29%) with only 1(6%) being diagnosed
with CAD on the first readmission.
Conclusion: Going by the standard criteria for diagnosing A/MH
where BP is180/ 110, through our study we could safely conclude
that 14 patients (83%) were either not reported with visual
changes or not being referred for ophthalmic evaluation. This
could also
Nocturnal non-dipping hypertension e A clinical
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cardiovascular adversity
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Background: Nocturnal hypertension is a common complication
of essential and secondary hypertension. Abnormal elevated
sleep blood pressure [nocturnal nondipper] is associated with
increased target-organ damage and adverse cardiovascular
outcomes.
Methods: Prospective cohort observational study. All known hy-
pertensive patients of any age and sex enrolled in the medical
clinics of central hospital,S.E.C.Railway, Bilaspur [C.G.] are stud-
ied. Period of study was from Apr’ 2012 to June’2014 [26 months].
Inclusion criteria - Hypertension as per JNC VII guideline are
selected from both sexes. History of taking more than three
antihypertensive drugs including one diuretics.
Ambulatory Blood Pressure Monitoring [ABPM] is done by two
equipments of model AMBULO 2400 [Mortara] with special soft
ware. Non-Dipper is identified by the software if there is <10%
drop of blood pressure during sleep hours. Morning 6 am to night
10 pm is awake period during which blood pressure is recorded
every 30 minutes and during sleep hours 10 pm to 6 am] it
recorded hourly. Microalbuminuria is done by urine MICRAL test.
Standard lab technique is used for Serum Uric acid and Homo-
cysteinemia. Left Ventricular Hypertrophy is recorded by 2-D color
echocardiography.
Results: Total no of patients enrolled were 212 [female¼46, Ages
ranged from 27 year to 80 years, [ average age was 49 +/- 13] non-
dippers were¼22[9.6%].Healthy controls were 72 [female¼14] ,
non-dippers were 3[0.04%]. Micralbuminuria in Dippers, non-
dippers and controls were 18,12 and 0 [p¼<0.0001] respectively.
High serum uric acid were in 24, 8 and 0 in dipper, non-dipper and
controls respectively [p¼<0.0001], High serum homocystein were
in 12,8 and 6 in dipper, non-dipper and controls respectively
[p¼<0.0001]. Left Ventricular Hypertrophy [LVH] were seen in 36,
18 and 2 of dipper, non-dipper and controls respectively
[p¼<0.0001].
Marker Dipper
[n¼190]
Non-dipper
[n¼22]
Control
[n¼72]
P value
Microalbuminuria 018(9%) 12 (54%) 0 ( 0%) <0.0001
High Uric acid 24 (12%) 08(36%) 0 (0%) <0.0001
LVH 36 (18%) 18 (81%) 2 (2.7%) <0.0001
High
homocystein
12 (6%) 08(36%) 06(8%) <0.0001
Conclusions: Non-dippers evaluated by the ABPM system can be
used as a clinical surrogate marker for oxidative stress and target
organ damage in chronic hypertension and hence this simple tool
can help the physician to implicate for appropriate therapeutic
plans.
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